United Therapeutics (NASDAQ:UTHR) CEO Sells $5,091,905.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $535.99, for a total value of $5,091,905.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at $21,714,562.87. This trade represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Stock Down 0.5%

UTHR opened at $529.05 on Friday. The business has a 50 day moving average price of $552.97 and a two-hundred day moving average price of $530.10. The company has a market cap of $22.46 billion, a PE ratio of 19.53, a P/E/G ratio of 1.78 and a beta of 0.58. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the business posted $6.63 earnings per share. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Raymond James Financial assumed coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday, May 7th. Bank of America lowered their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $644.82.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently made changes to their positions in UTHR. Torren Management LLC purchased a new stake in United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC purchased a new stake in shares of United Therapeutics during the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.